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Reanalysing genomic data by normalized coverage values
uncovers CNVs in bone marrow failure gene panels
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Supanun Lauhasurayotin1,2, Geoff D. Cuvelier3, Robert J. Klaassen4, Conrad V. Fernandez5, Yves D. Pastore6, Sharon Abish7,
Meera Rayar8, MacGregor Steele9, Lawrence Jardine10, Vicky R. Breakey11, Josee Brossard12, Roona Sinha13, Mariana Silva14,
Lisa Goodyear15, Jeffrey H. Lipton16, Bruno Michon17, Catherine Corriveau-Bourque18, Lillian Sung19, Iren Shabanova1, Hongbing Li1,
Bozana Zlateska1, Santhosh Dhanraj1,20, Michaela Cada2, Stephen W. Scherer1,21 and Yigal Dror1,2,20*
Inherited bone marrow failure syndromes (IBMFSs) are genetically heterogeneous disorders with cytopenia. Many IBMFSs also
feature physical malformations and an increased risk of cancer. Point mutations can be identiﬁed in about half of patients. Copy
number variation (CNVs) have been reported; however, the frequency and spectrum of CNVs are unknown. Unfortunately, current
genome-wide methods have major limitations since they may miss small CNVs or may have low sensitivity due to low read depths.
Herein, we aimed to determine whether reanalysis of NGS panel data by normalized coverage value could identify CNVs and
characterize them. To address this aim, DNA from IBMFS patients was analyzed by a NGS panel assay of known IBMFS genes. After
analysis for point mutations, heterozygous and homozygous CNVs were searched by normalized read coverage ratios and speciﬁc
thresholds. Of the 258 tested patients, 91 were found to have pathogenic point variants. NGS sample data from 165 patients
without pathogenic point mutations were re-analyzed for CNVs; 10 patients were found to have deletions. Diamond Blackfan
anemia genes most commonly exhibited heterozygous deletions, and included RPS19, RPL11, and RPL5. A diagnosis of GATA2related disorder was made in a patient with myelodysplastic syndrome who was found to have a heterozygous GATA2 deletion.
Importantly, homozygous FANCA deletion were detected in a patient who could not be previously assigned a speciﬁc syndromic
diagnosis. Lastly, we identiﬁed compound heterozygousity for deletions and pathogenic point variants in RBM8A and PARN genes.
All deletions were validated by orthogonal methods. We conclude that careful analysis of normalized coverage values can detect
CNVs in NGS panels and should be considered as a standard practice prior to do further investigations.
npj Genomic Medicine (2019)4:30 ; https://doi.org/10.1038/s41525-019-0104-9

INTRODUCTION
Inherited bone marrow failure syndromes (IBMFSs) are a group of
genetically heterogenoeuous disorders with impaired production
of one or more blood cell types. They usually present during
childhood and are frequently associated with physical malformations and a high risk of myelodysplastic syndrome (MDS),
leukemia, and other types of cancer.1,2 Over the last several
decades mutations in over 100 genes have been reported to cause
IBMFSs involving fundamental cellular pathways such as DNA
repair, telomere maintenance, and ribosome biogenesis.3–5 Thus
far, in all patients with IBMFSs and an identiﬁed genotype,
mutations in one gene have been found sufﬁcient to result in a
given phenotype. In our recently published data, 59% of the
patients with classiﬁed IBMFSs and 18% of the patients with
unclassiﬁed IBMFSs were found to have point mutations using a
NGS gene panel assay of about 70 known IBMFS genes.6
Copy number variants (CNVs are submicroscopic deletion or
duplications of DNA stretches ranging from several hundreds base

pairs to about 3 mb.7 They are common causes of inherited
diseases,8–10 and have been recognized as an important cause of
IBMFSs,10 for example, Fanconi anemia11,12 and Diamond Blackfan
anemia.13,14 We previously found that 16.4% of the IBMFS patients
without identiﬁed point mutations had pathogenic CNVs by single
nucleotide polymorphism arrays or comparative genomic hybridization arrays.3 Unfortunately, all current methods to detect CNVs
suffer from major limitations. Metaphase cytogenetics can only
detect variants greater than 3 mb and may miss abnormalities in
areas that are not well visualized. Furthermore, the exact size of
CNVs and whether the cytogenetic abnormality affects the copy
number of a speciﬁc gene cannot be determined by metaphase
cytogenetics. Comparative genomic hybridization arrays and
single nucleotide polymorphism arrays only detect CNVs that
are larger than 100 and 10–50 kb, respectively. Some important
genes may not be covered by these arrays due to difﬁculties in
designing proper probes. Last, small indels can be missed by
Sanger sequencing if the primers are designed to anneal to the
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normal sequence of the indel region. Whole genome sequencing
may overcome some of the above limitation;15 however, currently
the rate of CNV detection by whole genome sequencing is only
35–50%.
Since next generation sequencing (NGS) gene panel assays are
increasingly used to identify point mutations in clinical and
research laboratories,6,16,17 it would be of a great advantage if
they can also be used to detect CNVs. Several previous studies
suggested that CNVs can be inferred from NGS data.18,19
Importantly, Anders and Huber20 compared high-throughput
sequencing data by several different methods using a negative
binomial distribution and found that the normalized coverage
ratio can control type I error.
The aim of this study was to determine whether CNVs can be
detected in data from NGS gene panel assays using methods that
compare nucleotide read depth in test samples to normalized
control coverage values. We also aimed to characterize the
identiﬁed CNVs and to evaluate their clinical relevance. To address
these aims we studied a large number of patients with IBMFSs by
an IBMFS NGS gene panel assay.
RESULTS
Characteristics of the patients
Two hundred and ﬁfty eight IBMFS patients without a diagnostic
genotype were analyzed by the IBMFS NGS gene panel assay. Fifty
three percent were male. At time of analysis, 138 patients had a
speciﬁc syndromic diagnosis and 120 patients had an unclassiﬁed
IBMFS (Table 1). The most common diagnoses among tested
patients who had classiﬁed IBMFS and unknown mutations was
Table 1.

Clinical diagnosis of patients tested by the next generation
sequencing IBMFS gene panel assay.
Diagnosis

Number of patients tested
by the NGS panel

Diamond Blackfan anemia

43

Fanconi anemia

22

Kostmann/Severe congenital neutropenia 16
Shwachman-Diamond syndrome
Dyskeratosis congenita

12
12

Cyclic neutropenia

9

Inherited sideroblastic anemia

7

Congenital dyserythropoietic anemia

6

Congenital amegakaryocytic
thrombocytopenia

3

Familial thrombocytopenia

3

Radio-ulnar synostosis

2

Thrombocytopenia absent radii syndrome 2
Reticular dysgenesis
Unclassiﬁed (total)

1
120

With pancytopenia

56

With neutropenia

24

With anemia

11

With thrombocytopenia

6

With MDS/leukemiaa

20

Unknownb (3)

3

Total

258

a

Some of these patients initially underproductive cytopenia and then
developed myelodysplastic syndrome (MDS) and/or leukemia; others
presented with clones, myelodysplastic syndrome, or leukemia bunknown
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Diamond–Blackfan anemia, followed by Fanconi anemia, Kostmann/severe congenital neutropenia, Shwachman–Diamond syndrome, and dyskeratosis congenita. Among the 120 patients with
unclassiﬁed IBMFSs the largest group had global bone marrow
failure (pancytopenia). Importantly, 20 patients with unclassiﬁed
IBMFSs had clones/MDS/leukemia at the time they were tested by
the NGS gene panel assay.
Pathogenic point variants detected by the NGS gene panel
Pathogenic point variants were revealed in 90 patients (35%)
studied by the NGS panel batches 1–3. Among the 138 patients
with classiﬁed syndromes, pathogenic point variants were
identiﬁed in 73 patients (53%); whereas among the 120
unclassiﬁed patients only 17 (14%) were genotyped. The genes
identiﬁed to harbor pathogenic point variants by the NGS panel
assay are listed in Table 2. The identiﬁed genes were related to
various disorders on the IBMFS spectrum, including IBMFSs with
pancytopenia such as Shwachman–Diamond syndrome, Fanconi
anemia, and dyskeratosis congenita, IBMFSs with predominantly
anemia, such as Diamond–Blackfan anemia and inherited sideroblastic anemia, IBMFSs with predominantly neutropenia, such as
Kostmann/severe congenital neutropenia, and IBMFSs with predominantly thrombocytopenia, such as familial thrombocytopenia. The identiﬁed genes function in various cellular pathways,
including DNA repair (e.g., FANCA and FANCG), ribosome biogenesis (e.g., SBDS and RPS19), telomere maintenance (e.g., TINF2 and
DKC1), and hematopoietic signaling (such as GATA2). Analysis of
point variants from the NGS panel batch 1 and 2 was published
previously.6 Table 2 shows results of reanalysis of pathogenic
point variants from these batches and of those from batch 3.
Overall detection of CNVs by the NGS panel
Of the 258 patients analyzed by the panel 168 were not found to
have pathogenic point variants by the panel. Samples from 165 of
the patients without identiﬁed pathogenic point variants were
subjected to CNVs analysis using a computerized software
program. Of the 165 patients, 10 (6%) were found to have
pathogenic deletions in IBMFS genes (Fig. 1) using the strategy
described in the Methods. All identiﬁed deletions were validated.
Detailed description of the deletion and subjects are presented in
the following paragraphs and in Table 3.
Detection of CNVs in patients with previously established clinical
diagnosis
The largest group of patients with identiﬁed deletions were those
with Diamond–Blackfan anemia and included ﬁve patients. Three
of these patients had a heterozygous deletion that encompassed
the entire RPS19 gene (Fig. 2a–c and Supplementary Table 3).
Despite being siblings, having severe anemia since infancy,
markedly reduced bone marrow erythropoiesis and normal
erythrocyte adenosine deaminase (eADA) activity levels, these
patients had otherwise variable clinical phenotypes and outcome.
Patient 1 had scoliosis, patient 2 had large almond-shaped eyes,
and patient 3 had no physical malformations. These patients were
treated with prolonged courses of oral corticosteroids with varied
responses. Patient 1 responded well to corticosteroid treatment.
Patient 2 had only a partial response; his hemoglobin was still
lower than the normal level for age and he required few red blood
cell transfusions when he had intercurrent infections. Patient 3 did
not respond to corticosteroids and underwent matched unrelated
hematopoietic stem cell transplantation (HSCT) but developed
graft failure and died from sepsis after a second HSCT.
Patient 4 had one copy deletion in RPL5 from the promoter
region to exon 7 (Fig. 2d–f and Supplementary Table 4). In
addition to severe anemia, she had short stature, a large atrial
septal defect, sensorineural hearing loss and developmental delay.
Published in partnership with CEGMR, King Abdulaziz University

AR
AD
XR

Severe congenital
neutropenia

Myelokathexis/WHIM
Syndrome

Severe congenital
neutropenia

G6PC3
(NM_138387.2)

CXCR4
(NM_003467.2)

WAS
(NM_000377.2)
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AD

AD

AD
AD

Diamond–Blackfan anemia

Diamond–Blackfan anemia

Diamond–Blackfan anemia

Diamond–Blackfan anemia

Diamond–Blackfan anemia

RPL11
(NM_000975.5)

RPL5
(NM_000969.5)

RPL35A
(NM_000996.2)

RPS24
(NM_033022.3)

RPS26 (NM_
001029.5)

AD
AD
AD

AR
AR

Diamond–Blackfan anemia

Diamond–Blackfan anemia

Diamond–Blackfan anemia

Sideroblastic anemia

Congenital dyserythropoietic
anemia I

RPS29
(NM_001032.4)

RPS7
(NM_001011.4)

RPS10
(NM_001014.4)

SLC25A38
(NM_017875.4)

CDAN1
(NM_13877.4)

AD

AD

Diamond–Blackfan anemia

RPS19
(NM_001022.3)

Anemia

AR

AD

Inheri-tance

HAX1
Severe congenital
(NM_001018837.1) neutropenia

Cyclic neutropenia,Severe
congenital neutropenia

OMIM phenotype

p.Cys151Ser
Splicing site
p.Val197ArgfsX18
p.Leu59Pro
p.Ser126Leu
p.Leu206Ser
p.Cys71Phe

c.452 G > C
c.597 + 5 G > A
c.574_581dupGGCCGGCA
c.176 T > C
c.377 C > T
c.617 T > C
c.212 G > T

p.Asn57fsX12

c.166_169delACAA

c.2081 C > T/c.2015C > T

p.Pro694Leu/p.
Pro672Leu

p.Arg187Gln

p.Arg80His

c.239 G > A
c.560 G > A

p.Arg113X
Splicing site

c.337 C > T

p.Leu133Ser

c.457-3 C > G

c.398 T > C

Splicing site

p.Cys26Ser

c.77 G > C
c.63-3 C > A

p.Ser81ArgfsX3
p.Met1?

c.1 A > G

Splicing site
(branch point)

c.243delC

c.4-32_21del (12)

Splicing site
p.Met1?

c.4-2 A > G
c.1 A > G

p.Leu28del

p.Arg58ArgfsX53

c.174_175 delAG
c.78_80delCTT

p.Thr28MetfsX10

c.83delC

p.Ile124Met

p.Met1Ile

c.3 G > A

c.372 C > G

p.Trp52X

c.155 G > A
p.Cys21SerfsX33

p.Val6X

c.16delG

Splicing site

p.Arg62Gln

c.185 G > A

c.60_61delCT

p.Arg84LysfsX69

c.250_251delAG

c.158-1 G > C

p.Met1Ile
p.Val4LeufsX2

c.3 G > T

p.Ile294Thr

p.Arg334X

p.Gln305SerfsX82

c.10_13delGTTA

c.881 T > C

c.1000 C > T

c.906dupC

p.Trp44X

p.Trp156Gly

c.131 G > A

p.Ala61Val

c.182 C > T

Protein alteration

c.466 T > G

cDNA alteration

novel
novel/
published

comp hetero#

novel

novel^

published

published*

published*^

novel

published

published*

published*

published

published*^

published

published

published*

novel

published*

novel^

published

published

published

published*

published

published

published

published

published

published

Published*

published

published

novel

published

novel

novel

published^

published*

published*

published

Published
or Novel

homo

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

homo

homo

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

hetero

Zygo-sity

Pathogenic point variants detected by the inherited bone marrow failure syndrome NGS gene panel assay.

ELANE
(NM_001972.4)

Neutropenia

Gene

Table 2.

D
T

5.77

D

D

n/a

n/a

D

n/a

D

D

n/a

n/a

D

n/a

n/a

n/a

n/a

n/a

D

n/a

n/a

D

n/a

n/a

D

n/a

n/a

D

D

n/a

n/a

n/a

D

D

T

D

n/a

n/a

D

D

T

5.77

3.98

5.19

n/a

n/a

4.6

n/a

4.43

5.92

n/a

n/a

5.17

n/a

n/a

n/a

n/a

n/a

5.94

n/a

n/a

4.53

4.57

n/a

4.3

n/a

n/a

4.53

4.71

n/a

n/a

n/a

3.24

4.46

2.09

3.24

n/a

n/a

4.42

4.42

3.24

ConserSift **
vation (GERP)
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D

D

D

P

n/a

n/a

D

n/a

P

P

n/a

n/a

P

n/a

n/a

n/a

n/a

n/a

P

n/a

n/a

D

n/a

n/a

B

n/a

n/a

D

D

n/a

n/a

n/a

D

D

B

D

n/a

n/a

D

D

D

Poliphen2 **

D

D

D

D

n/a

n/a

D

n/a

D

D

n/a

n/a

D

n/a

n/a

n/a

n/a

n/a

D

n/a

n/a

D

n/a

n/a

D

n/a

n/a

D

D

n/a

n/a

n/a

D

D

Da

D

n/a

n/a

D

D

N

MutTaster **

M

M

M

H

n/a

n/a

M

n/a

M

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

H

n/a

n/a

n/a

n/a

n/a

H

n/a

n/a

n/a

M

n/a

n/a

n/a

H

H

L

H

n/a

n/a

M

H

L

MutAccessor **

D

D

D

D

n/a

n/a

D

n/a

D

D

n/a

n/a

N

n/a

n/a

n/a

n/a

n/a

D

n/a

n/a

D

n/a

n/a

D

n/a

n/a

D

D

n/a

n/a

n/a

D

D

N

D

n/a

n/a

D

D

N

Provean **

1
1

–
–

0.000008017/
0.00008498

2

3

1

–

3.978E−06

1

–

–

1
1

–

1

1

–

1

1

–

–

1

–

1

1

–

–

1

–

1

1

–

–

1

–

–

2

–

1
1

4
–

1

1
–

–

1
–

–

1

1

–

–

1

–

–

1

–

1
1

1
–

1

1
–

–

1
–

–

1

1
–

1
–
–

2

–

N

–

MAF (gnomAD)
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AD
AR
XR

Macro thrombocytopenia

Congenital amegakaryocytic
thrombocytopenia,

Wiskott–Aldrich syndrome

MYH9
(NM_002473.5)

MPL
(NM_005373.2)

WAS
(NM_000377.2)

AR

Fanconi anemia

ERCC4/FANCQ
(NM_005236.2)

AD or AR

AD Or AR

AD or AR
AR

Dyskeratosis congenita/
severe aplastic anemia

Dyskeratosis congenita

Dyskeratosis congenita

Shwachman-Diamond
syndrome

TERC
(NR_001566.1)

TERT
(NM_198253.2)

SBDS
(NM_016038.2)

XR

DKC1
Dyskeratosis congenita
(NM_001142463.2)

RTEL1
(NM_032957.4)

AD

TINF2
Dyskeratosis congenita
(NM_001099274.3)

FANCP/ SLX4
(NM_032444.4)

AR

AR

Fanconi anemia

FANCE
(NM_021922.2)

Fanconi anemia

AR

Fanconi anemia

FANCG
(NM_004629.1)

AR

AR

Fanconi anemia

FANCJ/BRIP1
(NM_032043.2)

FANCI
Fanconi anemia
(NM_001113378.1)

AR

Fanconi anemia

FANCA
(NM_000135.2)

Pancytopenia

AD

AD

Thrombocytopenia

ANKRD26
(NM_014915.2)

MASTL
Thrombocytopenia
(NM_001172303.2)

AR

Thrombocytopenia-absent
radius syndrome

AR

Inheri-tance

RBM8A
(NM_005105.4)

Thrombocytopenia

SEC23B
Congenital dyserythropoietic
(NM_001172745.2) anemia II

Gene

Table 2 continued

Splicing site

c.811 + 2 T > G

p.Arg672Cys
p.His412 Tyr
Splicing site
p.Ser41AlafsX18/
splicing site

c.1234 C > T
c.258 + 2 T > C
c.120delG/c.258 + 2T > C

Not applicable

n.83 T > C
c. 2014C > T

Not applicable
Not applicable

c.49 C > T
n.37 A > G/n.216_229del

X96/p.Pro17Ser

c.3442delC/

GGCGGGTCGCCTGC

p.Lys472Asn
p.Gln1149Argfs

c.1416 G > C

p.Thr458Met/

comp hetero#

homo

hetero

hetero

hetero

Comp hetero

comp hetero#

comp hetero

published*/
published

n/a
n/a

n/a

n/a

T

D

n/a

n/a

n/a

D

n/a

D

D

D

n/a

n/a

D

D

D

n/a

n/a

D

D

n/a

n/a

n/a

D

n/a

n/a

n/a

n/a

n/a

n/a

D

D

D

n/a

n/a

D

n/a

n/a

n/a

2.32

published$
published

3.76

n/a

n/a

n/a

4.86

n/a

0.204

-0.805

5.85

n/a

n/a

0.987

5.16

5.16

4.95

n/a

5.58

3.48

n/a

n/a

n/a

2.41

n/a

n/a

n/a

n/a

n/a

n/a

5.56

5.25

4.92

n/a

n/a

5.29

3.53

ConserSift **
vation (GERP)

novel

published*

published

Published/

published*

published*/

published

published*/

published

c.1373 C > T/

novel

p.Leu317Phe

Hemi

p.Lys39Thr

novel/

published

c.949 C > T

hemi

hetero

published

published*

novel

novel

published

published

published

published

p.Ile38Ser+

p.Ser245Tyr

c.734 C > A

hetero

hetero

homo

homo

homo

homo

homo

homo

published/
published

comp hetero#

c.112delA/ c.116InsC

p.Arg282Gly
p.Arg282His

c.844 C > G

p.Glu456Lys

p.Val926AlafsX38

p.Arg689Ser

c.845 G > A

c.1366 G > A

c.2776_2789delinsG

c.2065 C > A

p.Arg371Trp

Splicing site

c.1480 + 1 G > C
c.1111 C > T

p.Arg798X

p.Gln490Gln

c.1470 G > A
c.2392 C > T

p.Arg951Trp/

c.2851 C > T/

published

published

published*

published

published

novel

novel

novel

published

published*

homo

homo

p.Phe1263del
p.Gln549X

c.3788_3790delTCT

homo

c.1645C > T

homo

p.Val372AlafsX42

hetero

hemi

homo

c.2830_2831InsCAGCTTCAGGTTGAATTTC p.Asp944GlufsX12

c.1115_1118delTTGG

p.Leu53_Tyr54del

p.Arg102Cys

hetero
hetero

p.Arg1165Cys

hetero

published

novel/novel

comp hetero#

homo

Published
or Novel

Zygo-sity

p.His1521Arg

p.Ile1659TyrfsX3

5’UTR variant

p.Asn71His

p.Arg550X

Protein alteration

c.157_162delCTGTAC
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AD autosomal dominant, AR autosomal recessive, hemi hemizygous, hetero heterozygous, homo homozygous, LP likely pathogenic, N number of patients, VUS variant of unknown/uncertain signiﬁcance
#
Indicated presumed zygosity. Compound heterozygosity was determined based on the observation of two mutations on different alleles by the BAM ﬁle data. Otherwise the zygosity of patients with a disease
whose associated gene harbored two mutations were considered as having “presumed compound heterozygosity”
*Published previously as novel by our group (Ghemlas et al, J. Med. Genet. 2015).
**SIFT: D, damaging; T, tolerated
**POLYPHEN2: D, probably damaging; P, possibly damaging; B, benign; N, neutral **PROVEAN: D, damaging; N, neutral
**MutationTaster: disease causing automatic (Da); Disase causing (D); polymorphisam (SNP), polymorphism automatic (SNPa)
**MutattionAssessor: H, high; M, medium; N, neutral; L, low
$
Published in the Telomerase database (http://telomerase.asu.edu/)
^Splicing site variant was analyzed by the Human Splicing Finder and found to be pathogenic
The cases described in this table were analyzed in three batches. Analysis of point variants from batch 1 and 2 was published previously (Ghemlas et al., Journal of Medical Genetics 2015; 52; 575–84). This table
shows results of re-analysis of pathogenic point variants from these batches and of those from batch 3. There are some overlap between data in this table and data in supplemental tables 2–5 of the publication
in the Journal of Medical Genetics
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The patient did not respond to corticosteroid therapy and
required chronic red blood cell transfusions.
One copy deletion of the entire RPL11 gene was identiﬁed in
Patient 5 (Fig. 2g–i and Supplementary Table 5). This patient
presented with severe macrocytic anemia, reticulocytopenia and
high hemoglobin F at 2 years of age. Bone marrow examination
demonstrated pure red cell aplasia. Activity of eADA was elevated.
He was born with low birth weight and also suffered from failure
to thrive, bilateral complete cleft palate and cleft lip, tracheomalacia, subglottic stenosis, thumb abnormality and developmental
delay. He had a good response to corticosteroid therapy.
Patients 6 and 7 had a clinical diagnosis of thrombocytopenia
with absent radii syndrome. Using the NGS panel assay we
identiﬁed compound heterozygosity for a deletion on one allele of
RBM8A and a single pathogenic point variant on the other allele.
The cases have been previously reported,6 and the deletions were
also detected by Affymetrix SNP array.
Establishment of a syndromic diagnosis in patients with
unclassiﬁed IBMFSs based on CNV data
In three cases with an unclassiﬁed IBMFS, detection of CNVs led to
establishment of a syndromic diagnosis. Patient 8 had MDS. He
was found to carry a germline deletion of the entire GATA2 gene
(Fig. 3a–c and Supplementary Table 6). He had moderate
pancytopenia, high mean corpuscular volume, developmental
delay, attention-deﬁcit/hyperactivity disorder, retrognathia and
cutaneous warts on his hands. Bone marrow revealed hypocellular
specimen, decreased trilineage hematopoiesis and dyserythropoiesis. Bone marrow cytogenetic analysis showed 46,XY,+1,der(1;7)
(q10;p10)[23]/47,idem,+8[5]/46,XY[23].
Patient 9 had an unclassiﬁed IBMFS with pancytopenia and was
found to have a homozygous deletion of the FANCA gene from
exon 1 to exon 5 (Fig. 4a–c and Supplementary Table 7). The
patient presented with severe thrombocytopenia and mild
neutropenia at 8 years of age. Evaluation of his disease revealed
low birth weight, short stature, café-au-lait spots, absent right
kidney, and developmental delay. This patient did not respond to
immunosuppressive therapy for aplastic anemia and eventually
died after HSCT. No data about chromosome fragility testing and
genetic testing were reported to the registry.
Patient 10 presented with thrombocytopenia at 1 year 6 months
of age and then progressed to pancytopenia. This patient had
multiple anomalies as described in Table 3 and in our previous
published article.21 The patient was initially diagnosed with an
unclassiﬁed IBMFS. Due to an identiﬁed presence of compound
heterozygosity in PARN and further functional assays, the patient
was classiﬁed as having dyskeratosis congenita.21 Analysis of the
NGS reads by NextGene revealed both the heterozygous deletion
and pathogenic point variant. Compound heterozygosity was
conﬁrmed by parental testing.21
DISCUSSION
CNVs are an important cause of many genetic disorders including
IBMFSs.22 However, methods to detect CNVs lack sensitivity, and
frequently multiple diagnostic approaches and tests are required
to detect them. Herein, we investigated the ability to uncover
CNVs from a method primarily designed for nucleotide-level
analysis. We identiﬁed CNVs in a proportion of the cases where
pathogenic point variants were not found. Currently, NGS gene
panels are the standard method to search for genetic mutations.
Ideally, these panels would also used to detect CNVs at the same
time. This strategy would save time and decrease overall cost of
investigation. In the case of IBMFSs, the mutations (large
chromosomal changes, smaller CNVs, indels, and other point
mutations) and location (protein and nonprotein encoding genes)
are variable.6,10 Consequently, the time and cost of genetic
npj Genomic Medicine (2019) 30
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IBMFS patients
N=258

Point variant
analysis

Genotyped
N=90 (35%)

Non-genotyped
N=168 (65%)

- AD: 54/91 (59.3%)
- AR: 33/91 (36.3%)
- X-linked: 4/91 (4.4%)

CNV analysis
N=165

No deletions
fulfilling criteria
N=126

Deletions fulfilling
criteria N=39

CNVs deemed nonpathogenic N=29
- Heterozygous deleons
in AR disorders without
pathogenic point
variants: 29

Fig. 1

10 CNVs in
coding/promotor
regions

- AD: 6/10 (60%)
- AR: 4/40 (40%) (1 homozygous; 3
compound heterozygous for a CNV and
a pathogenic point variant)
- X-linked: 0

Validated

Workﬂow of cohort analysis and overall rates of pathogenic variant detection.

testing, if not done efﬁciently, could be prohibitive. This is
particularly important since many IBMFSs patients need treatment
urgently. Hence, extracting the maximum amount of information
out of each test is critically important. Our study indicates that
using NGS gene panel assay for both point mutations and
detection of CNVs increases the information that can be retrieved
from the assay.
Results of our study demonstrate that analysis of NGS gene
panel assays for CNVs can not only establish a genetic diagnosis
(such as identifying RPL5 mutations in patients with DBA), but can
also identify the speciﬁc diagnosis in unclassiﬁed or idiopathic
bone marrow failure syndromes. In this study, a diagnosis of
Fanconi anemia was made in a patient with unclassiﬁed IBMFSs
and a diagnosis of GATA2-related disorder in another with
idiopathic MDS. The identiﬁcation of a genetic diagnosis in the
case of DBA for example is critically important for genetic and
family counseling. Similarly, establishing a speciﬁc diagnosis of
Fanconi anemia in a patient with aplastic anemia is extremently
important given the treatment for Fanconi anemia is completely
different from that of idiopathic aplastic anemia. Importantly,
although positive chromosome breakage testing is the hallmark of
Fanconi anemia, in rare cases it is negative or difﬁcult to interpret
due to somatic genetic correction and lymphocyte mosaicism in
the peripheral blood chromosome fragility testing. Also, establishing a diagnosis of GATA2-related disorder in a patient with MDS
would completely change the approach to counseling, screening
and selection of family members as donors for bone marrow
transplantation for the affected subject.
To our knowledge, this is the ﬁrst study to analyze an IBMFS
gene panel by computerized software to detect small and large
size CNV. This software uses normalized coverage value to
compare with a deﬁned number of controls, which we set at 10.
Most of the detected CNVs were successive exons where at least
one of them showed a normalized coverage ratio of ≤0.33 in the
case of monoalleic deletion and a normalized coverage ratio of
≤0.05 in the case of bialleic deletion. Validation by an additional
method is recommended in case of borderline normalized ratios.
Detection of CNVs from NGS reads using the NextGene software
has some limitations. Even positive tests included the combination
of low dispersion and normalized coverage ratios that were found
in 3 sets of control data but some borderline results might still be
positive and may require validation. The combination of
npj Genomic Medicine (2019) 30

developing new algorithms to interpret borderline results and
correlating data with clinical phenotype may improve categorization of results as true positive versus false positive. CNV
duplications are difﬁcult to identify by the software. Further,
some duplicated fragments may not reside in the gene region and
may not disrupt the coding sequence.
In summary, NGS gene panels can be used to detect CNVs by
careful analysis of normalized coverage values. In our analysis
small CNVs encompassing one to few exons were detected from
an IBMFS NGS gene panel assay. Due to time and cost advantages,
we recommend that NGS gene panels routinely analyze for CNVs
before moving on to additional mutation detection strategies
such as CNV microarray or whole exome/genome sequencing.
Recently the cost of a clinical whole-exome sequencing (WES) test
dropped substantially (about $3500 (USA)) and became closer to
clinical NGS panels (about $1500 (USA)). Therefore, performing
WES as a ﬁrst line genomic diagnostic test can be considered,
particularly for designing virtual panels and only analyzing genes
of interest. In such cases, similar strategies to those described in
the present study can be applied to obtain CNV data from WES.
The results of our work have a signiﬁcant clinical relevance not
only to the ﬁeld of bone marrow failure, MDS and leukemia, but
also to many other disciplines where genetic testing by NGS gene
panels became the standard of care. Our study also provides
additional tools for research on the prevalence of CNVs in various
genetic disorders and on CNV detection by whole exome/genome
sequencing.
METHODS
Selection of patients
The patients included in this study were prospectively enrolled in the
Canadian Inherited Marrow Failure Registry (CIMFR) and did not have
known disease-causing mutations. The CIMFR and the experiments
outlines in this manuscripts were approved by the Research Ethics Boards
of the Hospital for Sick Children and the participating tertiary medical
centers in Canada. The study is conducted in accordance with the
Declaration of Helsinki, and informed written consent was obtained from
all patient or their guardian prior to enrollment. Patients who fulﬁlled
diagnostic criteria for an IBMFS23 in any of the 17 participating centers in
Canada were enrolled in the CIMFR since 2001, by the site research team.
The vast majority of children with IBMFSs are treated in one of the
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Diamond–Blackfan anemia Severe anemia,
decreased bone
marrow erythopiesis,
elevated eADA, no
response to
corticosteroid,
received chronic red
cell transfusion

Diamond–Blackfan anemia Severe anemia,
decreased bone
marrow erythopiesis,
elevated eADA, high
HbF, good response
to corticosteroid
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Thrombocytopenia
absent radii

7

Thrombocytopenia,
transient need for
platelet transfusion
in infancy

Thrombocytopenia,
transient need for
platelet transfusion
in infancy
Myelodysplastic syndrome Moderate
(CNV led to diagnosis of
pancytopenia,
GATA2-related disorder)
hypocellular bone
marrow,

Thrombocytopenia
absent radii
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shaped eyes
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corticosteroids
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Dispersion

0.0016-0.0039 1
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(NM_000969)

RPS19
hetero
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Zygosity
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Time from Gene
diagnosis (RefSeq
to CNV
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detection
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1

Main physical
malformations

Diagnosis at the time of
testing

Patient
no.

Hematological
abnormalities

Pathogenic copy number variants identiﬁed by the inherited bone marrow failure syndrome NGS gene panel.
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Hematological
abnormalities

Unclassiﬁed pancytopenia Thrombocytopenia,
later on
pancytopenia,
markedly
hypocellular bone
marrow, partial longterm response to
danazol

dyserythopoiesis,
marrow trisomy 8,
no available data
available about
treatment.
Unclassiﬁed pancytopenia Severe
(CNV led to diagnosis of
thrombocytopenia,
Fanconi anemia)
mild neutropenia,
hypocellular bone
marrow,
dyserythropoiesis,
reduced
megakaryocytes, no
response to
immunosuppressive
therapy,
underwent HSCT

Diagnosis at the time of
testing

Short stature, failure 128
to thrive,
microcephaly, global
developmental
delay, seizures, brain
demyelination,
brittle hair, mid face
hypoplasia, bulging
eyes, low set ears,
kyphosis, scoliosis,
right double
joint arms

Zygosity

Promoter –Exon5

Deletion region

PARN
comp
Exon15– Exon18
(NM_002582) heterowith
c.1045 C > T

FANCA
homo
(NM_000135)

Time from Gene
diagnosis (RefSeq
to CNV
accession)
detection
(months)

Low birth weight,
133
short staure, café-aulait spots, absent one
kidney,
developmental delay

deﬁcit/hyperactivity
disorder

Main physical
malformations
Dispersion

0.32–0.39

0.003-0.03

0.002–0.004 0.011-0.067

Ratio

18

16

1 (hetero)

7 (hetero)

Number of Number of
reports in reports in
helathy
patientsa
controlsa

CNV copy number variation, comp hetero compound heterozygosity, hetero heterozygosity, eADA erythrocyte adenosine deaminase, HSCT hematopoietic stem cell transplantation
a
Data about reported patients and controls were taken from the DECIPHER, ClinVAR, DGV, and gnomAD databases. Reported cases might have reported in more than one database
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from chromosome 19
Gray dots: data from
other chromosomes
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Fig. 2 Deletions in patients with Diamond Blackfan anemia. a Representative raw data dispersion with 95% conﬁdence intervals from one of
the three patients with RPS19 deletions (Patient 2). The dispersion analysis showed that 97.26% of the reads were within ﬁtted interval. The
purple dots represent data from chromosome 19 and show clear separation of dots outside the whole data (the RPS19 deletion) from other
dots on chromosome 19 (also purple) data and on other chromosomes (gray dots). b Gel electrophoresis shows clear reduction in the quantity
of signal of RPS19 exon 3 and exon 4 in the patients compared to controls. In this experiment FOXP2 and RPL11 were used as internal controls.
c Results of band densitometry from the gel electrophoresis. d Raw data dispersion with 95% conﬁdence intervals from patient 4 are shown.
Totally, 98.57% of the read were within ﬁtted interval. The purple dots on the left show clear separation of the RPL5 deletion from the whole
data and from the chromosome 1 data in each of the patient samples. e Gel electrophoresis shows clear reduction in the quantity of signal of
RPL5 exon 2–7 in the patient compared to controls. In this experiment FOXP2 and RPL11 were used as internal controls. f The lower panel
shows the results of band densitometry from the gel electrophoresis. g An RPL11 gene deletion in Patient 5 is shown. The ﬁgure shows the
raw data dispersion with 95% conﬁdence intervals from patient 5. Totally, 98.50 % of the reads were within ﬁtted interval. The purple dots on
the left shows clear separation of the RPL11 deletion from the whole data and from the chromosome 1 data in each of the patient samples. h
Gel electrophoresis shows clear reduction in the quantity of signal of RPL11 exon 2 and 4 in the patient compared to controls. In this
experiment RPL35A exon 7 was used as an internal control. i Band densitometry from the gel electrophoresis is shown. E indicates exon, P
indicates a patient number, and C indicates a healthy control subject.
participating CIMFR site centers. Patients information was collected at
study entry and periodically thereafter.
The eligibility criteria for the CIMFR included evidence of chronic bone
marrow failure in addition to either a family history of an IBMFS, or physical
malformations, or presentation earlier than one year of age. Patients
enrolled in the CIMFR who had positive genetic testing for an IBMFS gene
were excluded from this analysis. When possible, each case was assigned a
speciﬁc syndromic diagnosis by the participating center. Diagnoses were
reviewed centrally, and if necessary adjusted based on published
diagnostic criteria of speciﬁc IBMFSs1–3 after veriﬁcation with the
respective center. Cases that fulﬁlled the eligibility criteria, but did not
meet the clinical, laboratory and genetic diagnostic criteria for any known
IBMFS subtype were deﬁned as unclassiﬁed IBMFSs.24

NGS panel assay
Genomic DNA was extracted from peripheral blood, bone marrow
ﬁbroblasts, skin ﬁbroblasts or expanded peripheral blood T-cells.
Comprehensive NGS panel of known IBMFS genes was designed. Overall,
72, 77 and 141 genes, were included in the ﬁrst, second, and third analyzed
batch of patients, respectively (Supplementary Table 1). The Haloplex
Capture Kit (Agilent Technologies, Santa Clara, CA) was used for DNA
library preparation according to the manufacturer instructions. Brieﬂy, the
assay was based on a hybridization oligonucleotide pool, which covers
coding regions, 50 bp ﬂanking intronic regions that included splicing sites,
3′-untranslated regions that included potential translation regulatory
elements, and upstream promoter regions. The oligonucleotides were
150 mers with 3× tiling and a maximum of 10 bp overlap between
oligonucleotides. The panel design was submitted to the Agilent HaloPlex
Published in partnership with CEGMR, King Abdulaziz University

Design Wizard program (http://www.halogenomics.com/haloplex/customreagent-kits). Targeted fragments were ampliﬁed and were sequenced on
the Illumina HiSeq2500 platform as previous described.6

Variant analysis and ﬁltering strategy
The algorithm used to ﬁlter non-relevant point variants and the software
programs and websites used to predict protein damage, conservation and
minor allele frequency of pathogenic point variants are as previously
described.6 Brieﬂy, variants were deﬁned as “pathogenic” if they had been
reported as disease-causing in public databases. Novel variants were
considered “most likely pathogenic” if (1) they appeared in allelic dosage
that was consistent with the known inheritance mode of the disease, (2)
evolutionary conserved amino acid/s are affected, (3) the minor allele
frequency was <0.001 (4) the variant was considered damaging by at least
half of the following prediction software programs: PolyPhen2, SIFT,
MutationTaster, MutationAssessor, Provean. Splicing variants were
assessed by the Human Splicing Finder software program. Variants that
were reported in databases as having unknown signiﬁcance (usually due to
only one or two reported cases), but fulﬁlled the above criteria were
considered as “most likely pathogenic”. Variants that fulﬁlled most but not
all the above criteria remained of unknown signiﬁcance.

CNV analysis by normalized coverage values
Patients who were found to have no pathogenic point variants by the NGS
gene panel assay were analyzed for CNVs. We used the NextGene software
program, CNV Tools, to compare the coverage ratio of speciﬁc regions in a
test sample to ten samples of control projects, which were samples of sexnpj Genomic Medicine (2019) 30
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Fig. 3 Deletion of GATA2 gene in a patient with myelodysplastic syndrome. a The ﬁgure shows the raw data dispersion with 95% conﬁdence
intervals from patient 8. 97.73% of the reads were within ﬁtted interval. The purple dots on the left shows clear separation of the GATA2
deletion from the whole data and from the chromosome 3 data in each of the patient samples. b Gel electrophoresis shows clear reduction in
the quantity of signal of GATA2 exon 1, 3, and 5 in the patient compared to controls. In this experiment RPL11 exon 2 was used as internal
controls. c The panel shows the results of band densitometry from the gel electrophoresis.
matched healthy control subjects or patients with other disorders that are
not expected to have mutations in the analyzed gene. The beta-binomial
model was used to evaluate dispersion. The Hidden Markov Model was
used to calculate normalized count ratio and make a classiﬁcation of
speciﬁc regions as CNV. To minimize false positive results, we selected calls
with dispersion of ≤0.01, minimal normalized read counts of 100, minimal
region length of 50 bp and percentage of regions in which CNV calls are
expected to be made is ≤5%. After the test sample and 10 control sexmatched samples were loaded, a comparison was made ﬁrst to the average
coverage of all 10 controls; second, to median coverage of all 10 controls;
third, to the coverage of one control subject, whose coverage was closest to
the test sample. Only regions that were deemed deleted in all three
comparisons, were considered true deletions. Short variant calls (<50 bp)
were excluded since most often they represent random background noise.
Candidate heterozygous deletions were considered and selected for
validation studies if they fulﬁlled the following criteria: (1) the raw data
dispersion was ≥95% and the normalized coverage ratio was ≤0.33 in all
three types of comparisons to controls as indicated above; (2) multiple
successive exons with raw data dispersion of >95% and at least one of the
exons shows normalized coverage ratio of ≤0.33 in all three types of
comparisons to controls as indicated above.
Results were considered candidate homozygous deletions and were
selected for validation if they fulﬁlled the following criteria: (1) the raw data
dispersion was >95% and the normalized coverage ratio was <0.05 in all
three types of comparisons to controls as indicated above; (2) the raw data
npj Genomic Medicine (2019) 30

dispersion was >95% and multiple successive exons that at least one of
them shows normalized coverage ratio of <0.05 in all three types of
comparisons to controls as indicated above. Determination of CNV
frequency in the general population and degree of overlap with previously
reported CNVs was done automatically by the software using the Database
of Genomic Variants,25 and manually using the following databases:
Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/), ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/), DatabasE of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources (https://
decipher.sanger.ac.uk/) and Genome Aggregation Database (gnomAD,
https://gnomad.broadinstitute.org/).

Polymerase chain reaction
DNA was ampliﬁed using customized primers ﬂanking the regions that was
found to be deleted by the NGS panel. The primer sets are described in
Supplementary Table 2. Ampliﬁed DNA fragments were separated by
agarose gel electrophoresis and were visualized by ultraviolet light. Band
densitometry was determined using the ImageJ software.

Affymetrix SNP array 6.0
DNA was processed, hybridized to Affymetrix Genome-Wide Human SNP
array 6.0 (Affymetrix Inc., Santa Clara, CA, USA) and scanned as previously
described.21 Genotyping calls were determined using the Birdseed v.2
algorithm as described.6 CNV were considered novel if they did not appear
Published in partnership with CEGMR, King Abdulaziz University
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Fig. 4 Deletion of FANCA gene in a patient with unclassiﬁed inherited bone marrow failure syndrome. a The raw data dispersion with 95%
conﬁdence intervals from patient 9 are shown. Totally, 98.30% of the read were within ﬁtted interval. The purple dots on the left exhibit ratio
of <0.05 and are clearly separated from the whole data and from the other reads of chromosome 16. b Gel electrophoresis shows the absence
of ampliﬁed FANCA exon 2 and 5 in the patient compared to controls. In this experiment, FANCA exon 6 and RPL11 exon 2 were used as
internal controls. c The panel shows the results of band densitometry from the gel electrophoresis.
in healthy controls from The Center of Applied Genomics (Hospital for Sick
Children, Toronto, Canada).

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
The data that support the ﬁndings of this study are available on request from the
corresponding author [Y.D.]. The data are not publicly available since this can
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